查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
瀰漫性大 B 细胞淋巴瘤治疗的全球市场 - 2022-2029
市场调查报告书
商品编码
1146456

瀰漫性大 B 细胞淋巴瘤治疗的全球市场 - 2022-2029

Global Diffuse Large B-cell Lymphoma Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

预计 2021 年全球瀰漫性大 B 细胞淋巴瘤治疗市场价值 41.075 亿美元，在预测期内（2022-2029 年）以 7.50% 的复合年增长率增长。

瀰漫性大 B 细胞淋巴瘤 (DLBCL) 是最常见的非霍奇金淋巴瘤 (NHL) 类型。DLBCL 是一种影响 B 淋巴细胞的侵袭性（快速增殖）NHL。淋巴细胞是一种白细胞。B 细胞是产生抗体以抵抗感染的淋巴细胞，是淋巴系统的重要组成部分。

市场动态

全球瀰漫性大 B 细胞淋巴瘤治疗市场的增长是由 DLBCL（瀰漫性大 B 细胞淋巴瘤）发病率的增加、对靶向治疗的日益偏好以及技术与先进药物疗法相结合所带来的进步所推动的。

对靶向治疗的日益偏好预计将在预测期内推动增长

靶向治疗是最广泛提倡的瀰漫性大 B 细胞淋巴瘤治疗方法之一，因为它对健康细胞的毒性低于化学疗法。靶向治疗作用于与癌症相关的特定分子靶点。用于 NHL 的靶向治疗包括单克隆抗体、激□抑製剂、免疫调节剂和核输出抑製剂。利妥昔单抗是一种靶向治疗药物，用于治疗各种类型的 B 细胞非霍奇金淋巴瘤。它通过靶向一种称为 CD20 的分子起作用，该分子存在于正常 B 细胞和 B 细胞非霍奇金淋巴瘤的细胞表面。Ibrutinib 是一种靶向疗法，可抑制 Bruton 酪氨酸激□通路。套细胞淋巴瘤、边缘区淋巴瘤、小淋巴细胞淋巴瘤和 B 细胞淋巴瘤如慢性淋巴细胞白血病和华氏巨球蛋白血症已获批准。

分子生物学的最新进展提高了我们对 DLBCL 致癌物的理解，并导致了许多靶向治疗的发展，目前正在 I 期和 II 期试验中进行评估。Ibrutinib (Imbruvica) 是一种经 FDA 批准用于多种类型淋巴瘤的靶向疗法，目前正在 DLBCL 中进行测试，以查看它是否会以不同方式影响亚型。

高昂的处理成本可能会阻碍市场增长

治疗瀰漫性大 B 细胞淋巴瘤的高成本预计将限制接受治疗的个体数量，在一定程度上抑制市场增长。治疗瀰漫性大 B 细胞淋巴瘤 (RR DLBCL) 的费用可能非常昂贵，而且仅当考虑一线和二线治疗费用高达 200,000 美元时。在国际药物经济学和结果研究学会年度国际会议上发表的一项研究估计了三线治疗的终生直接医疗费用和该疾病的后续治疗费用。作者通过将治疗的平均售价加上 2017 年提供者的直接成本来计算三线治疗的成本。考虑的其他成本包括不良事件、治疗管理和监测、疾病管理以及未来的医疗保健成本。

终生成本从 600,000 美元到 750,000 美元不等，与三线治疗相关的不良事件占总成本的 30%。据信其他费用包括获得治疗 (28%) 和后续治疗 (21%)。RR DLBCL 的终生治疗费用接近并可能超过 100 万美元，包括一线和二线治疗的费用。

COVID-19的影响分析

COVID-19 大流行继续危害全球健康并阻碍全球经济。广泛观察到，先前存在瀰漫性大 B 细胞淋巴瘤的患者因 COVID-19 而出现更高的并发症。

正在进行的化疗对 COVID-19 患者预后的影响程度仍有争议，但至少一项大型研究发现，在诊断为 COVID-19 时接受治疗的瀰漫性大 B 细胞淋巴瘤患者发生严重并发症的风险增加.还有数据表明，淋巴瘤患者更容易感染 SARS-CoV-2。根据一份报告，在感染 COVID-19 的患者中，治疗强度越大，对临床结果的影响就越大。据报导，血液系统恶性肿瘤患者的发病率和死亡率都很高，这凸显了这一患者群体的脆弱性。

大多数中心在患者开始治疗时、按月或在他们入院接受治疗时在门诊对患者进行筛查。实施将根据 COVID-19 的流行程度和是否进行筛查而有所不同。阳性时的治疗时机和治疗方法需要个别判断。发表在 Blood Advances 上的一项研究发现，正在积极接受抗 CD20 抗体治疗的瀰漫性大 B 细胞淋巴瘤患者对 BNT162b2 mRNA（Pfizer Biointech, Inc.）COVID-19 疫苗的反应更好。显示正在下降。接受过抗 CD20 治疗的患者对 COVID-19 疫苗的反应可能会降低。绝对淋巴细胞计数高的患者也不太可能对疫苗产生反应。对于目前正在接受治疗的患者来说，这将是一个问题。

细分分析

免疫学和靶向治疗领域预计将在该细分市场中占据最大份额

靶向治疗是一种在不影响正常细胞的情况下，通过药物精准“靶向”癌细胞的癌症治疗方法。靶向疗法是有效的治疗方法，但许多人更喜欢将它们与其他疗法结合使用，例如常规或标准化疗、手术或放射疗法。研究和开发致癌的 DNA 改变和蛋白质已证明可用于设计针对此类蛋白质的有前途的疗法。不同类型的癌症有针对每种癌症的不同类型的药物。但是测试肿瘤可以确认目标，如果有药物，可以治疗它。由于传统化学疗法可以在伤害正常细胞的同时杀死癌细胞，因此预计靶向治疗领域将在预测期内增长。由于瀰漫性大 B 细胞淋巴瘤 (DLBCL) 的发病率不断增加，靶向癌症治疗市场正在扩大。例如，瀰漫性大 B 细胞淋巴瘤 (DLBCL) 是美国最常见的非霍奇金淋巴瘤 (NHL) 类型，约占美国新诊断 B 细胞 NHL 病例的 22%，根据到淋巴瘤协会。占领。每年有超过 18,000 人被诊断出患有 DLBCL。

为 DLBCL 开发新药和治疗方法的研发工作十分活跃。来自不同公司的多种产品正处于不同的临床试验阶段，预计将在预测期内进入市场。例如，Roche的 Glofitamab（抗 CD20 CD3 TCB，RG6026）是一种结合 T 细胞的双特异性抗体，旨在结合 B 细胞上的 CD20 和 T 细胞上的 CD3。通过同时作用于 B 细胞上的 CD20 和 T 细胞上的 CD3，可以通过激活 T 细胞并攻击和消除 B 细胞来治疗非霍奇金淋巴瘤等 B 细胞癌。

区域分析

北美占全球瀰漫性大 B 细胞淋巴瘤市场的最大市场份额。

由于瀰漫性大 B 细胞淋巴瘤 (DLBCL) 患者数量增加和公众医疗保健意识提高等因素，北美占据了市场主导地位。瀰漫性大 B 细胞淋巴瘤 (DLBCL) 是美国最常见的非霍奇金淋巴瘤 (NHL) 类型，约占美国新诊断 B 细胞 NHL 病例的 22 例，根据淋巴瘤社区.%.每年有超过 18,000 人被诊断出患有 DLBCL。该地区的 DLBCL 发病率以及非霍奇金淋巴瘤 (NHL) 发病率呈上升趋势，再加上潜在的人口变化，预计估计会增加。DLBCL 是一种成熟的 B 细胞肿瘤，由生髮中心和生髮后中心 B 细胞发展而来。

此外，越来越多的製造商正专注于采用合作和收购等无机增长战略，以加强其在復发/难治性瀰漫性大 B 细胞淋巴瘤领域的产品组合，这正在推动该地区的市场，有望促进增长。例如，FDA 最近批准了 Monjuvi (tafasitamab-cxix) 与来那度胺联合用于治疗復发或难治性瀰漫性大 B 细胞淋巴瘤 (DLBCL) 成年患者。

竞争格局

全球瀰漫性大 B 细胞淋巴瘤治疗市场竞争激烈，既有本地参与者也有全球参与者。为市场增长做出贡献的主要参与者包括 F. Hoffmann-La Roche Ltd、Novartis AG、Celltrion、Karyopharm Therapeutics、Kite Pharma、MorphoSys AG、AbbVie、CTI BioPharma、Seagen Inc.、TG Therapeutics 等增长。领先的公司正在采用多种增长战略，例如产品发布、收购和合作伙伴关係，这有助于伤口护理管理设备领域的发展。例如，2019 年 2 月 19 日，FDA 批准了 polatozumab 治疗復发或难治性 (R/R) 瀰漫性大 B 细胞淋巴瘤 (DLBCL) 患者，我们已授予 vedotin 优先审评权。

全球瀰漫性大 B 细胞淋巴瘤治疗市场——值得关注的主要参与者

F. Hoffmann La Roche

公司概况 Roche于 1896 年在瑞士巴塞尔成立。我们开发创新药物和诊断测试，帮助全球数百万患者。Roche是最早为患者提供靶向治疗的公司之一。结合製药和诊断方面的优势，罗氏比任何其他公司都更有能力进一步推进个性化医疗保健。三分之二的研发项目与伴随诊断有关。基因泰克于 2009 年 3 月成为罗氏集团的一部分。Roche是日本Chugai Pharmaceutical的大股东。

Product Portfolio 产品组合：Rituxan (Rituximab)/MabThera 是第一种治疗性单克隆抗体，靶向细胞表面带有 CD20 标记的细胞。这些细胞是许多血癌的核心，包括常见的淋巴瘤和白血病。

重大发展。2019 年 6 月，美国 FDA 批准Roche的多病毒疗法联合苯达莫司汀加利妥昔单抗（rituximab）用于既往接受过治疗的侵袭性淋巴瘤、瀰漫性大 B 细胞淋巴瘤 (DLBCL) 患者。获批 (BR)。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查目的和范围

第二章市场定义和概述

第三章执行摘要

  • 按药物类型划分的市场细分
  • 按给药途径划分的市场细分
  • 最终用户的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
    • 促进者
      • 越来越偏爱靶向治疗
    • 抑製剂
      • 飙升的治疗费用
    • 市场机会
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 专利分析
  • 管道分析
  • 流行病学
  • 供应链分析
  • 定价分析
  • 法律法规分析
  • 未满足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措
  • 概括

第 7 章 按药物类型

  • 免疫学/靶向药物
    • 利妥昔单抗（Rituxan）
    • polatuzumab vedotin 峰 (Polivy)
    • Tisagenlecleucel（Kymriah）（英文名：Kymriah）
    • tafasitamab-cxix (monjuvi)
    • Selinexar（XPOVIO）
    • Axicabutadiene siroleucer (Yescarta)
    • 其他（派姆单抗（Keytruda）、依鲁替尼）
  • 其他 - 合併用药

第八章 行政途径

  • 静脉给药途径
    • 口服给药

第 9 章最终用户

  • 医院
  • 癌症中心
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 11 章 竞争格局

  • 主要发展和战略
  • 公司股份分析
  • 产品基准
  • 值得关注的主要公司
  • 具有颠覆性技术的公司
  • 初创公司

第十二章公司简介

  • F. Hoffmann-La Roche Ltd
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Novartis AG
  • Celltrion
  • Karyopharm Therapeutics
  • Kite Pharma
  • MorphoSys AG
  • AbbVie
  • CTI BioPharma
  • Seagen Inc
  • TG Therapeutics

第 13 章瀰漫性大 B 细胞淋巴瘤药物的全球市场-DataM

简介目录
Product Code: DMPH1271

Market Overview

The global diffuse large b-cell lymphoma therapeutics market size was worth US$ 4,107.50 million in 2021 and is growing at a CAGR of 7.50 % during the forecast period (2022-2029).

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.

Market Dynamics

The global diffuse large b-cell lymphoma therapeutics market growth is driven by the increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma), increasing preference for targeted therapies and technological advancement coupled with advanced drug therapeutics.

Increasing preference for targeted therapies is expected to drive the growth in the forecast period

Targeted therapy is one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer. Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells. Ibrutinib is a targeted therapy that inhibits the Bruton's tyrosine kinase pathway. Mantle cell lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma, as well as chronic lymphocytic leukaemia and Waldenstrom macroglobulinemia, are among the B-cell lymphomas for which it has been approved.

Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently.

High cost of treatment is likely to hamper the market growth

The high cost associated with the treatment of diffuse large B-cell lymphoma is expected to restrain the market growth to a certain extent, as this limits the number of individuals undergoing the treatment. The cost to treat diffuse large B-cell lymphoma (RR DLBCL) can be high-and that's only taking into account first- and second-line treatments that can cost as much as $200,000. A study presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting estimated the lifetime direct medical costs of third-line and subsequent treatment costs for this disease. The authors calculated the cost of third-line therapies by adding the Average Sales Price of therapies, plus the direct costs to providers in 2017. Some of the other costs considered were adverse events, treatment administration and monitoring, disease management, and future healthcare costs

They discovered that lifetime costs can vary from $600,000 to $750,000, with the costs of adverse events related to third-line treatment representing 30% of the total cost. Treatment acquisition (28%) and subsequent therapy (21%) are the other costs considered included. The lifetime cost of treating RR DLBCL can approach and surpass $1 million after including the costs of first- and second-line therapies.

COVID-19 Impact Analysis

The COVID-19 pandemic continues to endanger global health and hinder the world economy; It has been widely observed that patients with existing diffuse large b-cell lymphoma experience higher complications due to COVID-19.

The degree to which ongoing chemotherapy impacts the outcome of patients with COVID-19 remains controversial, but at least one large study shows that individuals with diffuse large b-cell lymphoma undergoing treatment when diagnosed with COVID-19 are at high risk of severe complications. There are also data suggesting that patients with lymphoma have an increased susceptibility to infection with SARS-CoV-2. According to one report, the more intense the therapy, the greater the impact on clinical outcomes in patients who contract COVID-19. The high morbidity and mortality rates reported in patients with hematologic malignancies underscore the vulnerability of this patient population.

Most centers are screening patients beginning therapy in the out-patient clinic or even monthly on an on-going basis, or on admission to the hospital for treatment. Practices differ depending on the prevalence of COVID-19 and the availability of screening. The decision on when and how to treat in the face of a positive result must be individualized. Patients with diffuse large b-cell lymphoma who are actively undergoing treatment with an anti-CD20 antibody have an impaired response to the BNT162b2 mRNA (by Pfizer-BioNTech) COVID-19 vaccine, according to research published in Blood Advances. Patients who had any exposure to anti-CD20 therapy were less likely to have a response to the COVID-19 vaccine. Patients with an absolute lymphocyte count were also less likely to respond to the vaccine. This will create problem for patients who are presently taking therapies.

Segment Analysis

The immuno and targeted drugs segment is expected to hold the largest share in this market segment

Targeted therapeutics is a type of cancer treatment that uses drugs to precisely 'target' cancer cells without affecting normal cells. Although targeted therapy is an effective treatment, many individuals prefer to use it in combination with other therapies such as traditional or standard chemotherapy, surgery, or radiation therapy. Developments in research for DNA changes and proteins that drive cancer are proving effective to design promising treatments that target such proteins. For different types of cancers come different types of drugs that individually target distinct cancer. However, tumors are tested to check the target, and provide therapy if the drugs are available. As traditional chemotherapy can damage normal cells while killing cancer cells, the targeted therapeutics segment is expected to witness growth during the forecast period. Targeted cancer therapies market is growing due to the increasing incidences of diffuse large b-cell lymphoma (DLBCL). For instance, as per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

Robust R&D studies are underway for the development of new drugs and therapies for DLBCLs. Several products of different companies are in different phases of clinical trials and will be available in the market during the forecast period. For instance, Roche, Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin's lymphoma is under Phase 1 clinical trials is expected to complete by 2022.

Geographical Analysis

North America region holds the largest market share of global diffuse large b-cell lymphoma therapeutics market

North America dominates the market owing to the factor such as increasing prevalence of diffuse large b-cell lymphoma (DLBCL) cases and rising healthcare awareness among the peoples of the region. As per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year. The estimates are expected to increase due to the rising trend in the Non-Hodgkin Lymphoma (NHL) incidence as well as DLBCL incidence in the region, combined with underlying demographic changes. It is a mature B-cell neoplasm emanating from the germinal center & post germinal center B-cells.

Furthermore, increasing focus of manufacturers on adoption of inorganic growth strategies such as partnerships and acquisitions, in order to strengthen their product portfolio of relapsed or refractory diffuse large B-cell lymphoma which is anticipated to drive the market growth in the region. For instance, the FDA recently authorized Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL).

Competitive Landscape

The global diffuse large b-cell lymphoma therapeutics market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche Ltd, Novartis AG, Celltrion, Karyopharm Therapeutics, Kite Pharma, MorphoSys AG, AbbVie, CTI BioPharma, Seagen Inc., TG Therapeutics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the wound care management devices globally. For instance, On February 19, 2019, The FDA granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) (BR) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Global Diffuse Large B-cell Lymphoma Therapeutics Market - Key Companies to Watch

F. Hoffmann-La Roche Ltd

Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Product Portfolio: The company portfolio includes Rituxan (rituximab)/MabThera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia.

Key Developments: In June 2019, the U.S FDA approved Roche's Polivy in combination with bendamustine plus Rituxan (rituximab) (BR) for people with previously treated aggressive lymphoma i.e., diffuse large B-cell lymphoma (DLBCL).

The global diffuse large b-cell lymphoma therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing preference for targeted therapies
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Patent Analysis
  • 5.3. Pipeline Analysis
  • 5.4. Epidemiology
  • 5.5. Supply Chain Analysis
  • 5.6. Pricing Analysis
  • 5.7. Regulatory Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Immuno and Targeted Drugs*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Rituximab (Rituxan)
    • 7.2.4. Polatuzumab vedotin-piiq (Polivy)
    • 7.2.5. Tisagenlecleucel (Kymriah)
    • 7.2.6. Tafasitamab-cxix (Monjuvi)
    • 7.2.7. Selinexor (XPOVIO)
    • 7.2.8. Axicabtagene ciloleucel (Yescarta)
    • 7.2.9. Others (Pembrolizumab (Keytruda), Ibrutinib)
  • 7.3. Others-Combination Drugs

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Intravenous Route*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Oral

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 9.1.2. Market Attractiveness Index, By End-user Segment
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cancer Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Novartis AG
  • 12.3. Celltrion
  • 12.4. Karyopharm Therapeutics
  • 12.5. Kite Pharma
  • 12.6. MorphoSys AG
  • 12.7. AbbVie
  • 12.8. CTI BioPharma
  • 12.9. Seagen Inc
  • 12.10. TG Therapeutics

LIST NOT EXHAUSTIVE

13. Global Diffuse Large B-cell Lymphoma Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us